- Home
- DUO vs APRE Comparison
DUO vs APRE Comparison
Compare DUO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DUO | APRE |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.9M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DUO | APRE |
|---|---|---|
| Price | $1.66 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 112.0K | 70.4K |
| Earning Date | 03-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,189,313.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.30 | N/A |
| 52 Week Low | $1.24 | $0.90 |
| 52 Week High | $11.84 | $5.00 |
Technical Indicators
Market Signals| Indicator | DUO | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 43.65 |
| Support Level | $1.65 | $0.91 |
| Resistance Level | $1.77 | $1.14 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 7.14 | 39.31 |
Price Performance
Historical ComparisonAbout DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.